Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731936 | 0.84 | MEN1 (0.34) | MEN1KMT2AOPRD1CYP2D6SLC6A2 | |
| SCHEMBL1473655 | 0.84 | MEN1 (0.34) | MEN1KMT2AOPRD1CYP2D6SLC6A2 | |
| SCHEMBL538775 | 0.84 | MEN1 (0.34) | MEN1KMT2AOPRD1CYP2D6SLC6A2 | |
| SCHEMBL14141933 | 0.80 | LMNA (0.39) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2680329 | 0.79 | — | — | |
| SCHEMBL8062 | 0.78 | SMN1; SMN2 (0.37) | MEN1KMT2AOPRD1SMN1; SMN2 | |
| SCHEMBL10852709 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL4754387 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL11428307 | 0.74 | KMT2A (0.36) | MEN1KMT2A | |
| SCHEMBL17142024 | 0.72 | MEN1 (0.35) | MEN1KMT2AOPRD1CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329751-B2 | Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors | BRACCO IMAGING S.P.A. (IT) | 2012-12-11 | — | — | US | disclosed |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20100087505-A1 | Compounds Having Aryl-Sulphonamidic Structure Useful As Metalloproteases Inhibitors | BRACCO IMAGING S.P.A. (IT) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | MMP3, MMP7, MMP9 | MEN1 432/4885KMT2A 1798/4885OPRD1 2772/4885 |
| US-20100087505-A1 | Compounds Having Aryl-Sulphonamidic Structure Useful As Metalloproteases Inhibitors | MMP9, MMP1, ARSA | MEN1 2678/4885KMT2A 1159/4885OPRD1 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.